Two of the three stop codons follow this usage pattern, the ochre codon UAA accounts for 45% of the stop codons in the genome of " Ca. M. intestinalis" and respectively only 17% and 14% in the genomes of "Ca. M. alvus" and M. luminyensis and a same trend is observed for opal codon UGA (Additional file 1: Table S2).
The same trend was observed in a rat in vivo absorption study, in which the highest bioavailability of 134.6 ± 24.7% (relative to a commercial product, Sandimmun Neoral®, p < 0.01) was achieved when the supersaturation degree was 3.53.
Table 4 shows the concordance as a function of number of "anchor" markers when 50% of the samples where sequenced; the same trend was observed when a smaller proportion of samples were sequenced and used as the reference (data not shown).
The same variant showed a weaker, but still statistically significant, association in a general population cohort from the UK (Twin Early Development study or TEDS) (N = 1080, effect size 0.26%, P = 0.048) and the same trend was observed in a combined general population sample (N = 1471, effect size 0.007%, P = 0.075).
The same trend was observed in a subgroup analysis for non squamous tumors: high Bcl-2 expressers (n = 76) had a significantly better outcome compared to the low Bcl-2 group (median survival 25 vs. 13.8 months, log rank p = 0.04; Figure 3D) and Bcl-2 expression was associated with a 37% reduction in risk (HR = 0.63, 95% CI 0.4-0.98, p = 0.04).
Coefficients of variation for clutch length, egg number and laying rate were much larger in Taiwan than in France for the selected line except for the homozygous naked neck hens; the same trend was observed, with a lower magnitude, in the control line (Table 6).
When changes in Hb concentration on day 7 were expressed as a proportion of baseline Hb concentration, the same trend was observed with statistically significant decreases in the 0.75-mg/kg arm for heterozygous individuals and in the 0.4-mg/kg arm for homozygous/hemizygous individuals.
